Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease

Figure 1: Prasinezumab effect on motor signs progression assessed using MDS-UPDRS Part III in participants taking MAO-B inhibitors at baseline and those who were treatment-naïve at baseline: (A) Hypothetical strategy; (B) Treatment policy in OFF-state; (C) Treatment policy in ON-state. The MDS-UPDRS endpoints were analyzed using mixed models for repeated measures (MMRM). MAO-B, monoamine oxidase B; MDS-UPDRS, Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale. Error bars represent standard error. Fig. 2: Forest plot of prasinezumab effects on motor progression as measured by the MDS-UPDRS Part III (hypothetical strategy) across the primary pre-specified subpopulations. Adj., adjusted; CI, confidence interval; MAO-B, monoamine oxidase B; RBDSQ, Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire.